MarketBeat on MSN2d
GLP-1 Alternatives: 2 Stocks Benefiting From Weight Loss Trends
The supply shortage and high costs of GLP-1 weight loss drugs have created an opportunity for compounded GLP-1 treatments to ...
WHYY23h
After success with weight loss GLP-1 drugs, IBX patients face high costs after insurer drops coverage for obesity
Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.
The complicated world of compounded weight-loss drugs
On Super Bowl Sunday, many tuning into the big game saw a controversial ad from the telehealth company Hims & Hers. The ...
Medscape8d
Some Patients — And Doctors — Turn to Microdosing GLP-1s
Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...
Medscape1d
Study Finds Websites Aren’t Always Transparent About Compounded GLP-1 RAs
A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.
Managed Healthcare Executive6d
Hims and Hers Superbowl Ad Draws Controversy Over Safety
The GLP-1 compound drug sold by Hims and Hers is not approved by the FDA and its Super Bowl ad fails to list any risks ...
Novo Nordisk 'comfortable' with impact of Medicare price negotiations for GLP-1s: CEO
Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...
Cosmetic surgeons try to correct 'Ozempic face' for weight-loss drug users
Add surgical tweaks to fix so-called "Ozempic face" to the list of top trending cosmetic procedures, as tallied by the ...